x.com· @ · X·· 2026-04-22Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.
Body
From $RVMD Revolution Medicines, more strong data on KRAS drug and a glimpse of a ‘novel class’ beyond it
Last night's RM-055 data at #AACR26
https://t.co/pfbsXZcOKg via @angRchen
Heat 49 · 41 likes · 1 reply · 7 reposts
Source: x.com · x.com